Floatz logo

c46/ccr5/p140k lentiviral vector-transduced autologous hspcs

Hodgkins Lymphoma

Fred Hutchinson Cancer CenterCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

150 Active assets in the Hodgkins Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
CARMUSTINE
VIVUS LLC
Phase 2BBB
Carboplatin
St. Petersburg State Pavlov Medical University
Phase 2BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB

View all 50 →

Same molecule, other indications

c46/ccr5/p140k lentiviral vector-transduced autologous hspcs is also rated in:

HIV infectious diseaseDormant
CC
Indicative ·
43 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →